In line with the new needs of HIV-infected patients, the compound single-tablet formulation with less DDI is preferred
Lukang Pharmaceutical's Ticagrelor Tablets obtained the "Drug Registration Certificate"
Hengrui Medicine's Haitrombopag Ethanolamine Tablets Obtained the Qualification of US FDA Clinical Trial
Eli Lilly's Abecili Tablets Adds Indications, Opening a New Era of Early Breast Cancer Treatment
CSPC, Livzon... 92 new drugs were approved for clinical use, Chia Tai Tianqing attacked 5 billion varieties, and Kelun's first mouth-dissolving film came
The clinical trial application of Haisco's innovative drug HSK31858 tablets was accepted by the State Food and Drug Administration
Fangsheng Pharmaceutical’s Xuanqijian Bone Tablet was approved and issued by the State Drug Administration as the "Drug Registration Certificate"
Beida Pharmaceuticals BPI-361175 tablets obtained the U.S. FDA New Drug Clinical Trial Approval Notice
Shanghai Pharmaceutical Holding Subsidiary Rivaroxaban Tablets Approved for Production
Azithromycin tablets, a wholly-owned subsidiary of China National Pharmaceutical, passed the consistency evaluation of generic drugs
Qilu Pharmaceutical Group's clozapine tablets passed the consistency evaluation and a total of 96 reviews
Zuoli Pharmaceutical Polycarbophil Calcium Tablets Obtained Drug Registration Certificate
Nafuraphine Hydrochloride Orally Disintegrating Tablet, a joint product of 3SBio and Toray of Japan, submitted a marketing application
Fampridine Sustained-Release Tablets: High-quality real-world evidence helps patients to "win" step
Luye Pharma's new antidepressant drug Ansufaxine Hydrochloride Sustained-Release Tablets Phase II Clinical Data Released
The latest family standing drug list was announced. Why did the original metformin sustained-release tablets make the list again?
Naproxen Sodium Tablets, a subsidiary of Renfu Pharmaceutical Holdings, obtained the drug registration certificate
Shuanglu Pharmaceutical DT678 Tablets Obtained the Notification of Drug Clinical Trial Approval
The indications for first-line treatment of Iris vometinib mesylate tablets are planned to be included in the priority review
Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million